ArticleClinical case reports2026
Tjalma Syndrome-A Rare but Real Manifestation of Systemic Lupus Erythematosus.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tjalma syndrome, also known as pseudo-pseudo Meigs syndrome, is a rare complication of systemic lupus erythematosus (SLE) characterized by ascites, pleural effusion, and elevated CA-125 levels in the absence of malignancy. We report a case of a 22-year-old woman with SLE presenting with vulvar swelling, severe polyserositis, nephritis, and progressive respiratory failure. SLE was confirmed by strongly positive anti-dsDNA with low complement levels. Despite immunosuppressive and supportive therapy, the patient's condition rapidly worsened, and she died due to hyperkalemia-induced ventricular fibrillation. This case highlights the diagnostic challenges of Tjalma syndrome, the need for thorough exclusion of malignancy, and the importance of early immunosuppression in preventing fatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.